FDA Tightens SaMD Rules for Edge AI Validation: learn how the 2026 update affects 510(k), De Novo, latency thresholds, offline accuracy, and compliance costs for AI diagnostic software.

FDA Tightens SaMD Path for AI Diagnostics: learn how the new FDA SaMD guidance adds 6 months of real-world data to 510(k) and De Novo filings, reshaping U.S. market entry, timelines, and validation costs.

FDA Tightens SaMD Path for AI Diagnostic Software: learn how the new FDA SaMD real-world data validation rule may delay U.S. filings, reshape clinical partnerships, and impact Chinese exporters.

EU Draft SaMD Rule targets real-time AI compliance, signaling new EU demands for AI diagnostic software. Learn how it may reshape CE documentation, clinical evaluation, and edge audit logging.